BAY 11-7082

Catalog No.S2913 Synonyms: BAY 11-7821

BAY 11-7082 Chemical Structure

Molecular Weight(MW): 207.25

BAY 11-7082 is a NF-κB inhibitor, inhibits TNFα-induced IκBα phosphorylation with IC50 of 10 μM in tumor cells. Also inhibiting components of the ubiquitin system.

Size Price Stock Quantity  
In DMSO USD 120 In stock
USD 90 In stock
USD 270 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

6 Customer Reviews

  • The inhibition of IκBα phosphorylation by BAY11-7082 (10 µM) was confirmed using western blotting, and GAPDH was used as an internal reference.

    Cancer Lett, 2016, 378(2):131-41. BAY 11-7082 purchased from Selleck.

    Immunofluorescence images of Ishikawa cells showing the increase in the nuclear colocalization of ERa (red) and p65 (green) after E2 incubation. Nuclear colocalization is yellow. Treatment with ICI 182,780, PDTC or Bay inhibited the nuclear localization of both ERa and p65. Blue, DAPI-stained nuclei. All pictures were obtained the same day using the same microscope settings. Original magnification 3200, bar =50 um. Arrows, cytoplasmic ERa and p65 staining. ICI, ICI 182,780; Bay, Bay 11-7082.

    Int J Cancer 2014 135(2), 282-94. BAY 11-7082 purchased from Selleck.

  • Shown are Western blot analysis of Wnt5a expression in HDPCs treated with TNF-a (n=3–4). The gene expression level was normalized to GAPDH (n = 3–6). HDPCs were preincubated with pyrrolidinedithiocarbamic acid (PDTC, an NF-κB inhibitor), BAY11-7082 (an NF-κB inhibitor), SP600125 (a JNK inhibitor), SB203580 (a p38 inhibitor), or U0126 (an ERK inhibitor) before treatment with TNF-a.

    J Biol Chem 2014 289(30), 21028-21039. BAY 11-7082 purchased from Selleck.

    The effect of vaspin on TNF α -induced THP-1 cell adhesion to HAECS measured staining with VibrantDiO® Cell-Labeling Solution. The level of THP-1 cell adhesion to HAECs was measured at 4 hr after treatment with 25 -100 ng/mL vaspin in the presence or absence of 10 ng/mL TNF α . BAY11-7082 (10 uM, S2913, Selleckchem, USA), an inhibitor of NF- κ B, was used as a positive control.

    Cardiovasc Diabetol 2014 13, 41. BAY 11-7082 purchased from Selleck.

  • The irradiated Beas-2B cells were further co-cultured with U937 cells for 24 h after irradiation. In some experiments, Beas-2B cells were pretreated with 10 μM of U0126, SB203580, or necrostatin-1 for 1 h before irradiation, U937 cells were pretreated with 10 μM BAY 11-7082 1 h prior to cell co-culture, or 1 μg/ml anti-TNF-a antibody, 2 μg/ml anti-IL-8 antibody,40 nM SB225002 were added to the medium in the cell co-culture period. ***P < 0.001 compared with the non-irradiation control. #P < 0.05 ##P < 0.01 compared with cor-responding -irradiated cells.

    Mutation Research, 2016, 789:1-8. BAY 11-7082 purchased from Selleck.

    Reverse transcription-quantitative polymerase chain reaction assays revealed the effect of atorvastatin on visfatin-induced inflammation. Human coronary artery endothelial cells were incubated in the absence or presence of 50 ng/ml visfatin, with or without 50 nM FK866, 50 µM BAY11-0782 or 10 µM atorvastatin, for 24 h. (A) Atorvastatin downregulated visfatin-induced IL-6 gene expression (P-values from left to right vs. control: 0.0081, 0.0045, 0.0233 and 0.0057). (B) Atorvastatin decreased visfatin-induced IL-8 gene expression (P-values from left to right vs. control: 0.0096, 0.0037, 0.0043 and 0.0031). (C) Atorvastatin downregulated visfatin-induced IL-6 release (P-values from left to right vs. control: 0.0078, 0.0022, 0.0783 and 0.0382). (D) Atorvastatin inhibited visfatin-induced IL-8 release (P-values from left to right vs. control: 0.0094, 0.0032, 0.0039 and 0.0035). Significant differences were determined using Student's t-test; *P<0.05, **P<0.01 vs. visfatin control. IL-6, interleukin-6; IL-8, interleukin-8.

    Oncol Lett, 2016, 12(2):1438-1444. BAY 11-7082 purchased from Selleck.

Purity & Quality Control

Choose Selective IκB/IKK Inhibitors

Biological Activity

Description BAY 11-7082 is a NF-κB inhibitor, inhibits TNFα-induced IκBα phosphorylation with IC50 of 10 μM in tumor cells. Also inhibiting components of the ubiquitin system.
Targets
E2-conjugating enzymes [6]
(Cell-free assay)
IκBα phosphorylation [1]
(Tumor cells)
10 μM
In vitro

BAY 11-7082 completely and specifically abrogates NF-κB DNA binding, downregulating the NF-κB-inducible cytokine IL-6 and inducing apoptosis. [1] BAY 11-7082 (< 8 μM) is able to effectively inhibit both basal and TNFα stimulated NFκB luciferase activity in a dose dependent manner. BAY 11-7082 (8 μM) strongly inhibits the rate of proliferation in NCI-H1703 cells. [2] Bay 11-7082 (5 μM) rapidly and efficiently reduces the DNA binding of NF-kappaB in HTLV-I-infected T-cell lines and down-regulates the expression of the antiapoptotic gene, Bcl-x(L), whereas it has little effect on the DNA binding of another transcription factor, AP-1. Bay 11-7082-induced apoptosis of primary ATL cells is more prominent than that of normal peripheral blood mononuclear cells, and apoptosis of these cells is also associated with down-regulation of NF-kappaB activity. Bay 11-7082 (5 μM) selectively induces apoptosis of HTLV-I–infected T-cell lines associated with down-regulation of the expression of cyclin D1, cyclin D2, and Bcl-xL. [3] BAY 11-7082 (100 μM) prevents the nuclear translocation of p65 elicited by NMDA and the NMDA-induced increase of NF-κB binding in mouse hippocampal slices. BAY 11-7082 prevents NMDA toxicity occurring in CA1 region of hippocampal slices with 40% neuroprotection at 20 μM and 70% neuroprotection at 100 μM. [4] BAY 11-7082 at all concentrations tested significantly inhibits NF-κB p65 DNA-binding activity in adipose tissue, whereas in skeletal muscle, BAY 11-7082 at 50 μM and 100 μM significantly inhibits NF-κB p65 DNA-binding activity. BAY 11-7082 (100 μM) reduces IKK-β protein in human adipose tissue and skeletal muscle. BAY 11-7082 (100 μM) significantly decreases the release of TNF-α from adipose tissue, whereas the release of IL-6 and IL-8 is significantly inhibited at all concentrations of BAY 11-7082 tested. BAY 11-7082 (50 μM) significantly decreases the release of TNF-α, IL-6, and IL-8 in skeletal muscle. [5] BAY 11-7082 is also found to inactivate the E2-conjugating enzymes Ubc (ubiquitin conjugating) 13 and UbcH7 and the E3 ligase LUBAC (linear ubiquitin assembly complex), and thus induces B-cell lymphoma and leukaemic T-cell death. [6]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HeLa MXnGeY5kfGmxbjDBd5NigQ>? Ml7aNVDDqM7:TR?= M1LuRVEvPSCq MUThZo9tcXOqZYOgRnBCKGmwZIXj[YQhfXBicnXneYxifGmxbjDv[kBHViCjbnSgUW1RNToEoB?= NEn1OHozPTd7N{SzOy=>
SiHa  MkTiSpVv[3Srb36gRZN{[Xl? NFjWdGkyOMLizszN M{\DVVEvPSCq M2nIPYFjd2yrc3jld{BDWEFiaX7keYNm\CC3cDDy[Yd2dGG2aX;uJI9nKE[QIHHu[EBOVVBvOdMg M1nYT|I2Pzl5NEO3
ARPE-19 MnfiSpVv[3Srb36gRZN{[Xl? NHvS[HEyKM7:TR?= NIXvVlExNjViaB?= NFTBWnp{fXCycnXzd4V{KFSJLXnu[JVk\WUEoFnMMVjDqHC{b33veIVzKGGldHn2ZZRqd25? NVzKbm5XOjV3OUOwNlk>
HCT116 MVPGeY5kfGmxbjDBd5NigQ>? NXT5OJg2PSEQvF2= MYeyJIg> NV7JT2ZSTE2VTx?= NVfaSYd4[XS2ZX71ZZRmeyC|aXz5cYFzcW5vaX7keYNm\CCmb4fudoVofWyjdHnvckBw\iCleXPsbY4hTDF? M1W2ZlI2PDd7N{Kz
HMECs NXfhV2JmTnWwY4Tpc44hSXO|YYm= NGDoSmQ2yqEQvF2= MUCyJIg> M1HncYFjd2yrc3jld{BVVkZvzsGtbY5lfWOnZDDWR2FONTFiZYjwdoV{e2mxbtMg MYSyOVE6OzFzNh?=
A549  NIfQWWZHfW6ldHnvckBCe3OjeR?= M1Xv[VEx6oDLwsXN Mn;6NVIhcA>? NX3INphWe3WycILld5NmeyCGdnytN{BqdmS3Y3XkJIFkfGm4YYTpc44hd2ZicE[1 Mk\JNlUyPTZ6MEC=
RAW 264.7 NEfEVGRHfW6ldHnvckBCe3OjeR?= NFrLcno2yqEQvF2= MUixJIg> M4nkbolvcGmkaYTzJHRPTi4QsTDhcoQhUUxvMUKgdFQxKHC{b3T1Z5Rqd25? NFfoRYMzPTBzOUW2Oy=>
macrophages MVLGeY5kfGmxbjDBd5NigQ>? NIrOTpU2KML3TR?= MoOxN{Bp MXTwZZJ1cWGubImgZoxw[2u|IGnQSnMucW6mdXPl[EBmgHC{ZYPzbY9vKG:oIHnOU3Mh[W6mIFPPXE0zyqB? NWL2NYRrOjR7Nke4PVg>
HUVECs NEjKU3FHfW6ldHnvckBCe3OjeR?= M3;JXlMuOzBizszN NXvoWJVQOSCq MlzmdoVlfWOnczD0bIUh\XiycnXzd4lwdiCxZjDtbXIuOTR4YTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MlK0NlQ5PjN7NkW=
HeLa  NV2zO4FGTnWwY4Tpc44hSXO|YYm= M3K4NlXDqM7:TR?= NH7NZWgzPCCq MWHEUXNQ NEjJe2Zz\WS3Y3XzJJRp\SCjY4Tpeol1gSCxZjDUUmYu|rFicILvcY91\XMEoB?= MYGyOFY2Pzd6Mx?=
A549 NIPVOZVHfW6ldHnvckBCe3OjeR?= M2SyUFExKM7:TR?= M1fwRlHjiImq NWTBNmo3cW6qaXLpeJMhfGinIHnuZ5Jm[XOnIH;mJJBpd3OyaH:tTe67Ss7zIHnuJHBCOTB|LXnu[oVkfGWmIHP1cJR2emW|wrC= M1zDVVI1PjF{NEi4
HUVEC NETOfnlHfW6ldHnvckBCe3OjeR?= Mn\TNlAhyrWP M3PaWFAvPSCq MkG1SG1UVw>? MXLwdoV3\W62czD0bIUhcW6mdXP0bY9vKG:oIFXBUUBmgHC{ZYPzbY9v M1LkfVI1PTVzMkC5
A549RT-eto NEjwVndCeG:ydH;zbZMhSXO|YYm= M4DDd|ExyqEQvF2= NEi5OpYzPCCq MnPDSG1UVw>? NWqw[otE[WOlZXzldoF1\XNiRlXSU{1u\WSrYYTl[EBieG:ydH;zbZM> NYjmclhjOjR3M{WwPFM>
THP-1  MmX2SpVv[3Srb36gRZN{[Xl? NV7Z[Gs5OC5zL{JCpO69VQ>? MmrKNE42KGh? NHnEZYpi[nKxZ3H0[ZMhXE6ILd8xJJNm[3KndHnvckBieyC5ZXzsJIF{KHSqZTDpcoNz\WG|ZXSgd4VkemW2aX;uJI9nKEmOLU[gZY5lKEmOLUJOti=> M4jTVFI1Ozd6NUO2
SKCXCR2  MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\pNkDDvU1? NUmxN2hsPDhiaB?= NF3ZNoRl\WO{ZXHz[ZMh[2WubDDwdo9tcW[ncnH0bY9vKHOrZ37p[olk[W62bIm= MonBNlQ{PzZ5NEe=
SKCXCR2  NIHSRVdHfW6ldHnvckBCe3OjeR?= Mn;GNkDDvU1? NIniSJI1QCCq NWfYVnhZ[myxY3vzJJRp\SCFWFPMNU1qdmS3Y3XkJINmdGxiaX72ZZNqd25? MnXpNlQ{PzZ5NEe=
OVCXCR2 M4myT2Z2dmO2aX;uJGF{e2G7 NIG4blczKML3TR?= NHLmUZM1QCCq MlT1Zoxw[2u|IITo[UBEYEOOMT3pcoR2[2WmIHPlcIwhcW64YYPpc44> M2\Ec|I1Ozd4N{S3
DSCs  Mn7FSpVv[3Srb36gRZN{[Xl? MVSyMlUh|ryP MnTvNE42KGh? M3GydpJmfmW{c3XzJJRp\SCnbnjhcoNmdWWwdDDv[kBES0x{L1PDVlIh\XiycnXzd4lwdiCxZjDEV2N{KGmwZIXj[YQh[nliSVytN|M> MXiyOFM1PDJ2MB?=
WPs NEO1WWRHfW6ldHnvckBCe3OjeR?= NVPRPIFwOjVizszN M1i3TVUhdWmw NWq4TmNLe3WycILld5NmeyCDVGCgZY5lKH[ZRjDz[YNz\XSrb36= MoPENlQ{OzF{MEe=
A549RT-eto M4naeWFxd3C2b4Ppd{BCe3OjeR?= MUWxNOKh|ryP NIe5VokzPCCq MVzhZ4NmdGW{YYTld{BHOTRiZYj0doFkfC2vZXTpZZRm\CCjcH;weI9{cXNiY3;tZolv\WRidILlZZRu\W62IIfpeIghTjF2 M1zWdlI1OjJyN{K1
A549RT-eto MVvGeY5kfGmxbjDBd5NigQ>? NVjvVJVHOTEEoN88US=> NUPUeoFNOjRiaB?= MmTJ[IVkemWjc3XzJJRp\SCneIDy[ZN{cW:wIHzleoVteyCxZjDOSk3PwkJiYX7kJHAu\3EEoB?= M{PhRVI1OjJyN{K1
FaDu NYTuelNiTnWwY4Tpc44hSXO|YYm= M1PoZlIhcA>? M1LMb4lvcGmkaYTzJJA3PSCneIDy[ZN{cW:wIHHu[EBjdG:la4OgWG5H|rFvaX7keYNm\CCWV1nTWEBmgHC{ZYPzbY9v M{fP[VI1OjJyNkKy
IVD  M1rkfmZ2dmO2aX;uJGF{e2G7 M4K4ZVExyqEQvF2= NHTSbGE{KGR? MX\y[ZZmenOnczDUUmYu|rIkgKPt[YRq[XSnZDDzeZBxemW|c3nvckBw\iC2aHWg[Il{[yCvYYTybZghdWGlcn;tc4xm[3WuZYOgZYdoemWlYX6gZY5lKGOxbHzh[4VvKEmL MWOyOFE4PjhyOB?=
IVD  MVnGeY5kfGmxbjDBd5NigQ>? NGjBb3AyOMLizszN NYC4RpRJOyCm NXHLTXc5[WK{b3fheIV{KFSQRj5OtgKBm2mwZIXj[YQhfXBvcnXneYxifGmxbjDv[kBCTEGPVGOtOEBidmRiQVTBUXRUNTYEoB?= MmjzNlQyPzZ6MEi=
iNKT M3XydmZ2dmO2aX;uJGF{e2G7 MoTNNVAwOTByIN88US=> NULyc21ZOC53IHi= NIe3cJZqdmirYnn0d{B1cGViaX7keYN1cW:wIH;mJGEzSVJibWLORUBidmRib4To[ZIh\mGldH;y NF\lW3UzPDF{NES1Ny=>
PC-3 NVHnc4dITnWwY4Tpc44hSXO|YYm= MmrHNk42NzVxMUCg{txO MYCwMlUhcA>? MlLxZoxw[2u|IFnHSk1KUS2rbnT1Z4VlKFOWUzDtVm5CKGW6cILld5Nqd28EoB?= NWSyWXhFOjRyNUW1NlA>
THP-1  NYfudnAxTnWwY4Tpc44hSXO|YYm= NUe5bGQ{OTEEoN88US=> M2rtcVHDqGh? NGP4SmNi[m:uaYPo[ZMhfGinIHXm[oVkfCCxZjDyTHNROjdib36gV3IuSSCvUl7B MnrnNlM6Ozl|OUi=
A549 MWHGeY5kfGmxbjDBd5NigQ>? NXTwOnU{OcLizszN MoPIOFghcA>? MWnlcohidmOnczD0bIUhfXBvcnXneYxifGmxbjDv[kBK|rqEIHHu[EB{fWK|ZYH1[Y51KGSnY4LlZZNmKGmwIFLhfEBmgHC{ZYPzbY9vKGmwZIXj[YQh[nliY3;tZolv\WRic4TpcZVt[XSrb36= NVrR[GdXOjN7MECwPFA>
A549 MWDBdI9xfG:|aYOgRZN{[Xl? NUPTVVFlOcLizszN NYTvTXcyPDhiaB?= M2DM[5Jm\HWlZYOgeIhmKGOnbHyg[IVifGhiaX7keYNm\CCkeTDjc41jcW6nZDDzeIlufWyjdHnvci=> NVvKc4NLOjN7MECwPFA>
NCI-N87 M2f4Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1znfVExNzJyL{OwJO69VQ>? MW[2M|I1KGh? NF;aVpd{fXCycnXzd4V{KGOnbHygeoli[mmuaYT5JJNq\26rZnnjZY51dHl? NEPJ[GkzOzh2NkW0OS=>
AGS NV\FfIdnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVGxNE8zOC9|MDFOwG0> M{jmUlYwOjRiaB?= NHjROJl{fXCycnXzd4V{KGOnbHygeoli[mmuaYT5JJNq\26rZnnjZY51dHl? M3nGcVI{QDR4NUS1
MGC80-3 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUHOPZh7OTBxMkCvN|Ah|ryP NFSwPJo3NzJ2IHi= M1zGSpN2eHC{ZYPz[ZMh[2WubDD2bYFjcWyrdImgd4lodmmoaXPhcpRtgQ>? Mo\JNlM5PDZ3NEW=
HGC-27  NETJN5JHfW6ldHnvckBCe3OjeR?= MVm3MlUwOTVxM{Cg{txO MnPKOkBp M2rodYlv\HWlZYOgeIhmKGSncHjvd5Bpd3K7bHH0bY9vKGGwZDD1dE1z\We3bHH0bY9vKG:oIFpOvmLPuQ>? MoTjNlM5PDZ3NEW=
MGC80-3 M4TjbGZ2dmO2aX;uJGF{e2G7 MUm3MlUwOTVxM{Cg{txO M{nEc|YhcA>? NX;4dHFVcW6mdXPld{B1cGViZHXwbI9{eGixconsZZRqd25iYX7kJJVxNXKnZ4XsZZRqd25ib3[gTe67Ss7z NWP4[mdHOjN6NE[1OFU>
HGC-27  NWfiPJVxSXCxcITvd4l{KEG|c3H5 MW[3MlUwOTVxM{Cg{txO MVO2JIg> M1XvSYlv\HWlZYOgZZBweHSxc3nzJIlvKGFidHnt[U0h[W6mIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> M3L5S|I{QDR4NUS1
HBE  M4LlVGZ2dmO2aX;uJGF{e2G7 MWSxNO69VQ>? NHzPVFU{cA>? Mli3ZYJwdGm|aHXzJJRp\SCrbnPy[YF{\XNib3[gTWwuPiCneIDy[ZN{cW:wIHnu[JVk\WRiYomgR3NG NYTiUnZzOjN6MkSwPFk>
HepG2 MXfGeY5kfGmxbjDBd5NigQ>? M2XqfFAvOy9zL{Og{txO MnfBOFghcA>? NVPsXpVYemWmdXPld{BKVDZvaX7keYNm\CCST16xJIV5eHKnc4Ppc44> MnL3NlM4QTF6M{O=
THP-1 NG\KS3ZHfW6ldHnvckBCe3OjeR?= NHHpcZc2KML3TR?= NXTpN3dmOSCq NUXGcIM3TE2VTx?= NUXIe|VGcW6qaXLpeJMhVVSELXnu[JVk\WRiTldOvmIh[WO2aY\heIlwdg>? M2jIfVI{PjN2MkG4
THP-1  MnzDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEjBSYM2KML3TR?= MWW0M|gh\A>? MmjhSG1UVw>? M3\2Z5Jm\HWlZYOgeIhmKH[rYXLpcIl1gSCxZjDpcpRz[WOnbHz1cIFzyqCPVFK= M3ryflI{PjN2MkG4
MDM MmHiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVLSXVZHPSEEtV2= NYjocHV3PC96IHS= NGDCUJRFVVOR Mmq0doVlfWOnczD0bIUhfmmjYnnsbZR6KG:oIHnueJJi[2WubIXsZZLDqE2WQh?= NULURoJXOjN4M{SyNVg>
AM NGL5WmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnu1OUDDvU1? NVfsVm5CPC96IHS= NX\lOGVnTE2VTx?= Ml7CdoVlfWOnczD0bIUhfmmjYnnsbZR6KG:oIHnueJJi[2WubIXsZZLDqE2WQh?= M4XaTVI{PjN2MkG4
RAW 264  M3fucmZ2dmO2aX;uJGF{e2G7 NH3ZO4oxNjJvNTFCuW0> M2DUdVMxNzZyL{mwJI1qdg>? M1W0bolvcGmkaYTzJJRp\SCyaH;zdIhifGG|ZTDhZ5Rqfmm2eTDv[kBRXFBzQtMg MmX6NlM2Pzh|MEK=
HUVEC NELQd|ZHfW6ldHnvckBCe3OjeR?= NIfXfIIyOMLizszN MX[wMlUhcA>? M13uXWROW09? MnLkZ492dnSncnHjeIV{KHSqZTDsc5N{KG:oIGTp[VIhdVKQQR?= MUeyN|U3OzZ|Mh?=
HT29 Mk\OSpVv[3Srb36gRZN{[Xl? NIPmbGMyOC9|MD:xNFAh|ryP NWHYUndNOSCq MYPpcohq[mm2ZYOgZo91cCCWV1XBT{1qdmS3Y3XkJJAyODBicILvZ4V{e2mwZx?= M37C[|I{PTJ5MUW0
HT29 MkS2SpVv[3Srb36gRZN{[Xl? M3LPS|ExNzNyL{GwNEDPxE1? NGfSV|AyKGh? NV72T2hocW6qaXLpeJMhXE6ILXnu[JVk\WRicHjvd5Bpd3K7bHH0bY9vKGGwZDDk[Ydz[WSjdHnvckBw\iCLzsrC{tE> MXWyN|UzPzF3NB?=
MM.1S MYHBdI9xfG:|aYOgRZN{[Xl? NIjXTZI{OCEEtV2= MUizJIg> M4S1Solv\HWlZYOgUW0h[2WubDDk[YF1cCCrbo\vcJZmeyCwZXPyc5Nqew>? M33aSlI{PTJ5MUW0
KMS-12-BM M3\2S2Fxd3C2b4Ppd{BCe3OjeR?= MmWxN|AhyrWP MmTUN{Bp NGfITHZqdmS3Y3XzJG1OKGOnbHyg[IVifGhiaX72c4x3\XNibnXjdo9{cXN? NYLxfIY6OjN3MkexOVQ>
BAFs NV;uWFgxTnWwY4Tpc44hSXO|YYm= NIjyUXoxNjVxMdMg{txO NWCwd|ZHOjRiaB?= NW\ueZRLcW6qaXLpeJMhXE6IzsGvSGVZKGmwZIXj[YQhS1mSMUnBNeKhfHKjboPjdolxfHN? Mk\jNlM1QDV2NUe=
SP6.5 M2W2UWZ2dmO2aX;uJGF{e2G7 MknqOUDPxE1? NHLKU3QzKGh? NEHsSpFl\WO{ZXHz[ZPDqHS{YX7zcI9k[XSrb36gc4YheDZ3IHnuJJRp\SCwdXPs[ZV{yqB? NX\URphjOjN2NEOwPFY>
VUP Ml74SpVv[3Srb36gRZN{[Xl? MnniOUDPxE1? MkTyNkBp Mo\h[IVkemWjc3XzxsB1emGwc3zvZ4F1cW:wIH;mJJA3PSCrbjD0bIUhdnWlbHX1d:Kh MlHYNlM1PDNyOE[=
OCM1 NF7NPHVHfW6ldHnvckBCe3OjeR?= NUK3W3BoPSEQvF2= M3\2XVIhcA>? M1;IVIRm[3KnYYPld:KhfHKjboPsc4NifGmxbjDv[kBxPjViaX6geIhmKG63Y3zleZPDqA>? NEDISGUzOzR2M{C4Oi=>
OM431 Mn3YSpVv[3Srb36gRZN{[Xl? NV;MbJdYPSEQvF2= M33CNFIhcA>? MVnk[YNz\WG|ZYRCpJRz[W6|bH;jZZRqd25ib3[gdFY2KGmwIITo[UBvfWOuZYXzxsA> MljuNlM1PDNyOE[=
SP6.5 NV;vSIpWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnXUNk42NTJyIN88US=> MWmyOEBpyqB? MV\JR|UxRTVizszNMEBmgGirYnn0d{B{fHKxbnegZY51cS2ycn;sbYZmemG2aY\lJIVn\mWldIOgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= MUKyN|Q1OzB6Nh?=
VUP NULsTZFPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUOyMlUuOjBizszN NEjKfWEzPCCqwrC= MlfCTWM2OD13IN88UUwh\XiqaXLpeJMhe3S{b37nJIFvfGlvcILvcIln\XKjdHn2[UBm\m[nY4TzJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy M{DzdFI{PDR|MEi2
OCM1 NVXGNG9VT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXm3VJdWOi53LUKwJO69VQ>? M1H2ZVI1KGkEoB?= MULJR|UxRTVizszNMEBmgGirYnn0d{B{fHKxbnegZY51cS2ycn;sbYZmemG2aY\lJIVn\mWldIOgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= MUeyN|Q1OzB6Nh?=
OM431 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXHMVXFsOi53LUKwJO69VQ>? NHHLW5czPCCqwrC= NV7JXoFRUUN3ME21JO69VSxiZYjobYJqfHNic4Tyc45oKGGwdHmtdJJwdGmoZYLheIl3\SCnZn\lZ5R{KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz Ml3ONlM1PDNyOE[=
SP6.5 NVnGR4d1SXCxcITvd4l{KEG|c3H5 NISwSWI2KM7:TR?= Ml;iNlQhcMLi NVzLS4hlcW6mdXPld{BieG:ydH;zbZPDqA>? NV7TZmc3OjN2NEOwPFY>
VUP MWHBdI9xfG:|aYOgRZN{[Xl? MWe1JO69VQ>? Mn30NlQhcMLi M2H3colv\HWlZYOgZZBweHSxc3nzxsA> M2XyNFI{PDR|MEi2
OCM1 NUHBUGZ5SXCxcITvd4l{KEG|c3H5 NWDsWWVVPSEQvF2= NWTtUXprOjRiaNMg NWfpPIJHcW6mdXPld{BieG:ydH;zbZPDqA>? NF3Nb|YzOzR2M{C4Oi=>
OM431 M3nMcGFxd3C2b4Ppd{BCe3OjeR?= NGXPNmM2KM7:TR?= M3nDc|I1KGkEoB?= M4XBeIlv\HWlZYOgZZBweHSxc3nzxsA> M2jv[lI{PDR|MEi2
SP6.5 NFf4e4dHfW6ldHnvckBCe3OjeR?= M1zVeFUh|ryP M{O2WlEzKGh? MmrrdoVlfWOnczD0bIUhdWmpcnH0bY9vyqB? NHnM[HMzOzR2M{C4Oi=>
VUP M1\ITWZ2dmO2aX;uJGF{e2G7 M4DSNVUh|ryP M2WxSFEzKGh? MV3y[YR2[2W|IITo[UBucWe{YYTpc47DqA>? M1ThU|I{PDR|MEi2
OCM1 NELFN4VHfW6ldHnvckBCe3OjeR?= MkWxOUDPxE1? NX\wW|BoOTJiaB?= MYXy[YR2[2W|IITo[UBucWe{YYTpc47DqA>? MV:yN|Q1OzB6Nh?=
OM431 NGewVHlHfW6ldHnvckBCe3OjeR?= NETXOnk2KM7:TR?= NULieZduOTJiaB?= NGTiVGJz\WS3Y3XzJJRp\SCvaXfyZZRqd28EoB?= MlLSNlM1PDNyOE[=
HBL-1  MmGyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlLON:Kh|ryP NUPSd5Q1OjRxNEivO|IhcA>? M1TTc2ROW09? NYTGZY05e2yxd4OgZ4VtdCCpcn;3eIghdW:mZYP0cJk> MX6yN|Q1OTd|MB?=
RAW 264.7 NU\NTHVMTnWwY4Tpc44hSXO|YYm= Mn7jNk0yPSEQvF2= NV6xb5hYOSCq NWnq[3lGTE2VTx?= Mlj5d5VxeHKnc4Pld{B1cGViYXP0bZZifGmxbjDv[kBKU0tiZnHtbYx6KG2nbXLldpM> MY[yN|Q1OTd|MB?=
IL-1R  NVruepRITnWwY4Tpc44hSXO|YYm= M3f2d|IuOTVizszN MVGxJIg> NXTPcIl2TE2VTx?= M1nxNJN2eHC{ZYPz[ZMhfGinIHHjeIl3[XSrb36gc4YhUUuNIH\hcYltgSCvZX3i[ZJ{ M1;FcVI{PDRzN{Ow
RAW 264.7 M33WNWZ2dmO2aX;uJGF{e2G7 NGfWSIIyPSEQvF2= MVKxJIg> NWrsZ4s3TE2VTx?= MYjzeZBxemW|c3XzJJRp\SCjY4TpeoF1cW:wIH;mJIFv\CCMTlu= Mnv2NlM1PDF5M{C=
IL-1R  MmS0SpVv[3Srb36gRZN{[Xl? M3L3PFE2KM7:TR?= MUCxJIg> NE\hWnlFVVOR MXzzeZBxemW|c3XzJJRp\SCjY4TpeoF1cW:wIH;mJIFv\CCMTlu= MmPENlM1PDF5M{C=
U2OS MWHGeY5kfGmxbjDBd5NigQ>? M1H4U|E2KM7:TR?= M4fsO|EhcA>? NGjBdG1FVVOR MUfwdoV3\W62czD0bIUhVFCVLTDvdkBKVC1zLYP0bY12dGG2ZXSg[o9zdWG2aX;uJI9nKEt4Mz3wWYIh[2ijaX7zxsA> MVuyN|Q1OTd|MB?=
MT‐1  MnTrSpVv[3Srb36gRZN{[Xl? MoLpPOKhyrWv NELzcms{KGh? NV75b2Z6\GWlcnXhd4V{KHSqZTDs[ZZmdHNib3[gdQKBmFOWQWSzJIFv\CCy4pEQOGVDWDF? MV2yN|I4QDR5OR?=
MT‐2  NXP1d2Q1TnWwY4Tpc44hSXO|YYm= MWG4xsDDvW1? NX7jNGV{OyCq MV7k[YNz\WG|ZYOgeIhmKGyndnXsd{Bw\iCy4pEQV3RCXDNiYX7kJJDjiJB2RVLQNS=> NEDVPGwzOzJ5OES3PS=>
MT‐1  MVTGeY5kfGmxbjDBd5NigQ>? M2jBXljDqML3bR?= MVWzJIg> M4npSoRm[3KnYYPld{B1cGVibHX2[Yx{KG:oIITo[UBxPjVic4XieY5qfCCxZjDOSwKBmM78QtMg NHTCVnkzOzJ5OES3PS=>
MT‐2  NUPD[GVWTnWwY4Tpc44hSXO|YYm= Ml64POKhyrWv MmXtN{Bp NF3RV3Vl\WO{ZXHz[ZMhfGinIHzleoVteyCxZjD0bIUheDZ3IIP1ZpVvcXRib3[gUmbjiJEQulNCpC=> NYjtbGc2OjN{N{i0O|k>
MCF-7  M{HaW2Z2dmO2aX;uJGF{e2G7 NYXJ[pdGOi53LUG1JO69VQ>? NH\4NZoxNjViaB?= MUPEUXNQ NITzRnpk[XW|ZYOgeIhmKGe{YXT1ZYwhdG:|czDv[kBk\WyuIHHkbIV{cW:w M{Hoc|I{ODl|MkK3
HaCaT  M3HjWGZ2dmO2aX;uJGF{e2G7 M3K4e|UvOMLizszN M1\YOlHDqGkEoB?= NE\BcphifHSnboXheIV{KHSqZTDUR29JNWmwZIXj[YQheHKxZIXjeIlwdiCxZjDJUE03yqB? MUmyN|A1OTF4OB?=
A549  MXTGeY5kfGmxbjDBd5NigQ>? NGjlTnQyKGh? MlizbY5pcWKrdIOgUHRCNWmwZIXj[YQhW1BvQTDtVm5CKHC{b3T1Z5Rqd28EoIPp[45q\mmlYX70cJk> Mn\LNlMxOzF{MUO=
OA chondrocytes  M1PqOWZ2dmO2aX;uJGF{e2G7 NH;ufoYyOCEQvF2= NV2xOZJnOSCq NXv4N5Zb[myxY3vzJJRp\SCDR1WtRnNCNWmwZIXj[YQh\2WwZT;wdo91\WmwIHX4dJJme3Orb36gc4YhT1KSN{igc5IhS0:[LUKgLJA9OC5yNTm= NUHSSpY1OjJ7OEKyNlg>
RAW264.7 MnjkSpVv[3Srb36gRZN{[Xl? M3Hn[VE2KM7:TR?= M3:wSFE2NTF{MDDtbY4> NWfHNJh3[myxY3vzJJRp\SCycn;keYN1cW:wIH;mJG5QNCCSR1WyMEBidmRiVF7GMe6y NIe5T2ozOjd2NUWyNy=>
RAW264.7 NFHaS4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVO1MVMxKM7:TR?= MoizNlQhcA>? MlnGbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MnftNlI4PDV3MkO=
HBL6 NGXMXGZCeG:ydH;zbZMhSXO|YYm= M{XrTlAvPS93L{K1JO69VQ>? MoK0Ok8zPCCq NXTBSG1L\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIFv\CCuZXXh[JMhfG9iYYDvdJRwe2m|IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{wrC= NIDo[Y4zOjB5NEiyNC=>
HT29  NWfWVII6TnWwY4Tpc44hSXO|YYm= Mn7DNU0yOCEQvF2= MkD2NVDDqGh? M17OS4lv[3KnYYPld{BJVy1zIH3SUmEh[W6mIIDyc5RmcW5iZYjwdoV{e2mxbh?= M2\p[VIyPjJyOU[0
Ca9–22 NX3ZWWdGSXCxcITvd4l{KEG|c3H5 Mon5NVDDqM7:TdMg M{H4SFEhcA>? MlS5Z49ueGyndHXsfUBqdmirYnn0d{BCVEFvUFTUMYlv\HWlZXSgZZBweHSxc3nz NGO4WGQzOTF|OES4NC=>
Ca9–22 MnzDSpVv[3Srb36gRZN{[Xl? M2LZdVExyqEQvF5CpC=> M4rqTFEhcA>? NIHtcpZkd22ybHX0[Yx6KGGkcn;nZZRmeyC2aHWgRWxCNVCGVD3pcoR2[2WmIFrOT{Bi[3SrdnH0bY9v MnTyNlEyOzh2OEC=
A-549 M{\vUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF3je2wyOMLizszNxsA> MlnYNlQwPDhiaB?= M4Hpe4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGgeIlu\S2mZYDlcoRmdnRibXHucoVz MXmyNFg3PjB2Mx?=
AP MorxSpVv[3Srb36gRZN{[Xl? NYiyc45KPS9zMDFOwG0> M2POZVQ5KGh? MXzkc5dvemWpdXzheIV{KHSqZTDCRWQheHKxdHXpckBt\X[nbDDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NV3C[oFyOjB3OU[2OFU>
AQ1 MYrGeY5kfGmxbjDBd5NigQ>? NVTNRXhoPS9zMDFOwG0> NYexRXZ[PDhiaB?= MVXkc5dvemWpdXzheIV{KHSqZTDCRWQheHKxdHXpckBt\X[nbDDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? M4fUZlIxPTl4NkS1
AP MUjGeY5kfGmxbjDBd5NigQ>? NWfaZ|A{OjBizszN M3rYT|QwQCCq MVXkc5dvemWpdXzheIV{KHSqZTDCRWQheHKxdHXpckBt\X[nbDDhJJRqdWVvZHXw[Y5l\W62IH3hco5meg>? M3zNWVIxPTl4NkS1
AQ1 MVzGeY5kfGmxbjDBd5NigQ>? MlLaNlAh|ryP NHvweYU1NzhiaB?= NXm1WHZL\G:5boLl[5Vt[XSnczD0bIUhSkGGIIDyc5RmcW5ibHX2[Ywh[SC2aX3lMYRmeGWwZHXueEBu[W6wZYK= NUWzVFZ2OjB3OU[2OFU>
THP-1 MU\GeY5kfGmxbjDBd5NigQ>? MXS1xsDPxE4EoB?= M33zW|AvPSCq M2e1b4F1fGWwdXH0[ZMhfGinIFzQV{1qdmS3Y3XkJJAuUc78Qt8xJJBzd3SnaX6gZpkhPzJn MUGyNFMxQTdzOB?=
K562 MkTHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHPrWGYzNTNyIN88US=> MYWyOEBp M{\JTGlEPTB;ODFOwG0tcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? Mkf1NVk3PDZ6MEe=
Jurket M3;3W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV[yMVMxKM7:TR?= NYLjc3FvOjRiaB?= MnTGTWM2OD15LkGg{txONCCrbnjpZol1eyClZXzsJIdzd3e2aDDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= M{XKXFE6PjR4OEC3
U937 NI\zNodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlW1Nk0{OCEQvF2= MVGyOEBp MUPJR|UxRTFyLkWg{txONCCrbnjpZol1eyClZXzsJIdzd3e2aDDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NV;xUFNROTl4NE[4NFc>
PBMC NWnuU5BmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1fYeVIuOzBizszN MV6yOEBp NIDIbXZKSzVyPUSwMlIh|ryPLDDpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NGfkfGkyQTZ2NkiwOy=>
K562 MUPBdI9xfG:|aYOgRZN{[Xl? MUWyMVIxyqEQvF5CpC=> MYmyOEBp MmHjbY5lfWOnczDhJIRwe2VvZHXw[Y5l\W62IHHwc5B1d3Orcx?= NFrCXGcyQTZ2NkiwOy=>

... Click to View More Cell Line Experimental Data

Protocol

Cell Research:[2]
+ Expand
  • Cell lines: NCI-H1703 cells
  • Concentrations: ~8 μM
  • Incubation Time: 12 hours
  • Method: Cells are transfected with siRNA in 96-well microtiter plates and then cultured for 72 hours in complete NSCLC medium, treated with BAY 11-7082 for 12 hours. Cells are incubated with [3H]thymidine for 3 hours. The cells are collected on filters using an automatic cell harvester and radioactivity on the filters is measured by β-scintillation counting.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 41 mg/mL (197.82 mM)
Ethanol 10 mg/mL (48.25 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order:
5% DMSO+corn oil
For best results, use promptly after mixing.
8mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 207.25
Formula

C10H9NO2S

CAS No. 19542-67-7
Storage powder
in solvent
Synonyms BAY 11-7821

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

IκB/IKK Signaling Pathway Map

IκB/IKK Inhibitors with Unique Features

Related IκB/IKK Products

Tags: buy BAY 11-7082 | BAY 11-7082 supplier | purchase BAY 11-7082 | BAY 11-7082 cost | BAY 11-7082 manufacturer | order BAY 11-7082 | BAY 11-7082 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID